Craving reduction varies widely and is not guaranteed
Amid this surge, Novo Nordisk, the company behind GLP-1 drugs Ozempic and Wegovy, has experienced a remarkable rise in its stock price, from roughly $50 per share in 2022 to upwards of $142 in June 2024
Its safety profile is excellent, effects are well-documented, and benefits extend beyond physical performance
Tirzepatide and retatrutide also mimic a second hormone called glucose-dependent insulinotropic polypeptide (GIP) to reduce appetite and blood sugar
CV Outcomes in Observational Studies: CVD-REAL Registries In a large multinational study (CVD-REAL [Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors]: 6 European countries and the United States), a treatment with SGLT-2 inhibitors versus other glucose-lowering agents was associated with a lower risk of hospitalization for HF and all-cause death (Table 6)
We recommend all patients considering taking any oral medications at the same time as semaglutide make decisions cautiously and alongside a healthcare provider. Tirzepatide, marketed as Mounjaro and Zepbound, was a different story